Form	Form PTO-1449 (modified)			Atty. Docket No. Serial No. UTSC:684US/SLH 10/010,763		
List of Patents and Publications for Applicant's NFORMATION DISCLOSURE STATEMENT			Applicant Isaiah J. Fidler Corazon D. Bucana		CENTER	
FEB 1 A TOTAL STATE OF THE PARTY OF THE PART	(Use several sheets if necessi	ary)	Filing Date: November 2, 2001	Group: 1645	1600	
RADEWIRT OF	U.S. Patent Documents See Page 1	1	Patent Documents See Page 1	Other Art See Page 1	2900	

U.S.	Patent	Docume	nts
------	---------------	--------	-----

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	Al	5,340,744	8/23/94	Lavker et al.	436	63	10/12/93
	A2	5,427,916	6/27/95	Gewirtz et al.	435	. 6	8/10/94
	A3	5,599,681	2/4/97	Epstein et al.	435	7.23	10/13/94

Foreign Patent Documents

Exam.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation		
GN	C1	Akiyama et al., "Growth factor and growth factor receptor localization in the hair follicle bulge and associated tissue in human fetus," J. Invest. Dermatol., 106(3):391-396, 1996.		
	C2	Bergler et al., "The expression of epidermal growth factor receptors in the oral mucosa of patients with oral cancer," Arch. Otorhinolaryngol., 246(3):121-125, 1989.		
	C3	Bergmann et al., "Insulin-like growth factor I overexpression in human pancreatic cancer. evidence for autocrine and paracrine roles," Cancer Res., 55:2007-2011, 1995.		
	C4	Bruns et al., "Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma," Cancer Res., 60:2926-2935, 2000.		
	C5	Bruns et al., "In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice," Neoplasia, 1:50-62, 1999.		
	C6	Chan et al., "A common human skin tumour is caused by activating mutations in β-catenin," Nat. Genet., 21:410-413, 1999.		
d	C7	Ciardiello et al., "Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A," J. Nat'l Cancer Inst., 88:1770-1776, 1996.		

25111125.1

EXAMINER:	. (-2	DATE CO	NSIDERED:	11/5/0	رر

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

		· ·
	Atty. Docket No.	Serial No.
,	UTSC:684US/SLH	10/010,763
Applicant's	Applicant	•
	Isaiah J. Fidler	
TATEMENT	Corazon D. Bucana	
	Filing Date:	Group:
ורא)	November 2, 2001	1645
Foreign I	Patent Documents	Other Art
s	ee Page 1	See Page 1
•	ratement ry) Foreign I	Applicant's Applicant Isaiah J. Fidler Corazon D. Bucana Filing Date:

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation		
Syl	C8	Gill et al., "Monoclonal anti-epidermal growth factor receptor antibodies which are inhibited of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity," J. Biol. Chem., 259:7755-7760, 1984.		
	C9	Green and Couchman, "Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition," J. Invest. Dermatol., 85(3):239-245, 1985.		
	C10	Green and Couchman, "Distribution of epidermal growth factor receptors in rat tissues during embryonic skin development, hair formation, and the adult hair growth cycle," J. Invest. Dermatol., 83(2):118-123, 1984.		
	Cll	Green et al., "Distribution and number of epidermal growth factor receptors in skin is related to epithelial cell growth," Dev. Biol., 100:506-512, 1983.		
	C12	Hansen et al., "Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development," Am. J. Pathol., 150(6):1959-1975, 1997.		
	C13	Harmon et al., "Bisindolylmaleimide protein-kinase-C inhibitors delay the decline in DNA synthesis in mouse hair follicle organ cultures," Skin Pharmacol., 10:71-78, 1997.		
	C14	Korc et al., "Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha," J. Clin. Invest., 90:1352-1360, 1993.		
	C15	Lokshin et al., "Mechanisms of growth stimulation by suramin in non-small-cell lung cancer cell lines," Cancer Chemother Pharmacol., 43:341-347, 1999.		
	C16	Luetteke et al., "The mouse waved-2 pheontype results from a point mutation in the EGF receptor tyrosine kinase," Genes Dev., 8:399-413, 1994.		
	C17	Maiorano and Favia, "Expression of phosphotyrosine in squamous cell carcinoma of the oral mucosa. Preliminary study," Boll. Soc. Ital. Biol. Sper., 71(5-6):157-162, 1995.		
Y	C18	Maiorano et al., "Prognostic implications of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa," J. Pathol., 185:167-174, 1998.		

25111125.1			
Examiner:	Lyen	DATE CONSIDERED:	11/5/04
EXAMINER: INTIAL	IF REFERENCE CON	SIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH N	APEP609; DRAW LINE THROUGH

				•	
F	orm PTO-1449 (modified)		Atty. Docket No. UTSC:684US/SLH	Serial No. 10/010,763	TECH
JC144 JOHN	ist of Patents and Publications for INFORMATION DISCLOSURE S		Applicant Isaiah J. Fidler Corazon D. Bucana		CENTER
Z Z Z Z	(Use several sheets if necessary)		Filing Date: November 2, 2001	Group: 1645	1600
M & TRADE	U.S. Patent Documents Fo See Page 1		Patent Documents See Page 1	Other Art See Page 1	2900

(Other	Art (Including Author, Title, Date Pertinent Pages, Etc.)
Exam.	Ref. Des.	Citation
5U.	C19	Murillas et al., "Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure," EMBO J., 14(21):5216-5223, 1995.
	C20	Nameda et al., "Endotoxin-induced L-arginine pathway produces nitric oxide and modulates the Ca2+ activated K+ channel in cultured human dermal papilla cells," J. Invest Dermatol., 106:342-345, 1996.
	C21	Saleh et al., "Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation," Cancer Biother. Radiopharm, 14:451-463, 1999.
	C22	Smythe et al., "The activity of HMG-CoA reductase and acetyl-CoA carboxylase in human apocrine sweat glands, sebaceous glands, and hair follicles is regulated by phosphorylation and by exogenous cholesterol," J. Invest. Dermatol., 111:139-148, 1998.
	C23	van Oijen et al., "Increased expression of epidermal growth factor receptor in normal epithelium adjacent to head and neck carcinomas independent of tobacco and alcohol abuse," Oral Dis., 4(1):4-8, 1998.
	C24	Wagner et al., "Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth in vitro and in vivo," Gastroenterology, 114:798-807, 1998.
	C25	Wang et al., "Effects of in vivo treatments of nicotine and benzo[a]pyrene on the epidermal growth factor receptor in harnster buccal pouch," <i>Toxicology</i> , 107:31-38, 1996.
	C26	Wang et al., "Identification of epidermal growth factor receptor in human buccal mucosa," Arch. Oral Biol., 35(10):823-828, 1990.
	C27	Whitcomb et al., "Immunohistochemical mapping of epidermal growth-factor receptors in normal human oral soft tissue," Arch. Oral Biol., 38(9):823-826, 1993.
	C28	Yamada et al., "Evaluation of epidermal growth factor receptor in squamous cell carcinoma of the oral cavity," Oral. Surg. Oral Med. Oral Pathol., 73:67-70, 1992.
·	C29	Yamanaka et al., "Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness," Anticancer Res., 13:565-569, 1993.
	C30	Yamanaka et al., "Overexpression of HER2/neu oncogene in human pancreatic carcinoma," Hum. Pathol., 24:1127-1134, 1993.

25111125.1	
EXAMINER: S. June	DATE CONSIDERED: (1/5/04)
	OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH NCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Farm I							<u>_</u>	
ronn i	PTO-144	19 (modified)		Atty. Docket UTSC:684US			Serial No.	
List of l	Patents a	nd Publications f	or Applicant's		UTSC:684US 10/010,763 Applicant			
			••	1	Isalah J. Fidler			
INF	ORMATI	ON DISCLOSURE	STATEMENT	Corazon D. E	ucana	, ·	- No No.	
(Use several sheets if occessary)				Filing Date:	Filing Date: November 2, 2001		p: JUL 3 0 2002	
U.S. Patent Documents Foreign				n Patent Documen				
See Page 1				See Page 1		See Page 1		
			II C Do	tent Docum	onto			
Exam.	Ref.	Document	Date	Name	Class	Sub	Filing Data of	
init.	Des.	Number	Date	Name	Class	Class	Filing Date of App.	
	A4	5,480,968	1/2/96	Kraus et al.	530	326	11/10/92	
			Foreign F	Patent Docui	ments			
Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No	
				Ĺ. <u></u>				
(Other .	Art (Includi	ing Autho	or, Title, Date	Pertin	ent Pag	jes, Etc.)	
Exam. Init.	Ref. Des.	Citation						
Su	C31	Albanell et al., "Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 ('Iressa') in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition," European Journal of Cancer, 37(Supp. 6): S159, 2001.						
	C32	Parker et al., "Preferential activation of the epidermal growth factor receptor in human colon carcinoma liver metastases in nude mice," J. of Histochemistry and Cytochemistry, 46(5):595-602, 1998.						
1	C33	Pollack et al., "Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice," J. Pharmacology and Experimental Therapeutics, 291(2):739-748, 1999.						
V		and antitumor e	ffects in athymi	inomas with CP-358 ic mice," J. Pharma	3,774: dynar cology and	nics of rece Experiment	ptor inhibition in situ	
4	·	and antitumor e	ffects in athymi	ic mice," J. Pharma	cology and i	Experiment	ptor inhibition in situ al Therapeutics,	
4	·	and antitumor e	ffects in athymi	ic mice," J. Pharma	OF PAPERS	Experiment	ptor inhibition in situ al Therapeutics,	
4		and antitumor e	ffects in athymi	ic mice," J. Pharma	cology and i	Experiment	ptor inhibition in situal Therapeutics, RECEIVE	
4		and antitumor e	ffects in athymi	ic mice," J. Pharma	OF PAPERS	Experiment	ptor inhibition in situ	
4		and antitumor e	ffects in athymi	ic mice," J. Pharma	OF PAPERS	Experiment	RECEIVE AUG 0 1 2002	
5189785.1		and antitumor e	ffects in athymi	ic mice," J. Pharma	OF PAPERS	Experimenta	RECEIVE AUG 0 1 2002	

EXAMINER: DATE CONSIDERED: [/5/oc]

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.